CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 
 

XFOR's Net Income Growth by Quarter and Year

X4 Pharmaceuticals Inc's Net Income results by quarter and year




XFOR Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - -2.31 -21.87 -20.18
III Quarter September - -55.71 -21.21 -19.64
II Quarter June - -24.02 -24.22 -26.92
I Quarter March -51.77 -29.10 -35.91 -18.40
FY   -51.77 -111.14 -103.21 -85.14



XFOR Net Income first quarter 2024 Y/Y Growth Comment
X4 Pharmaceuticals Inc in the first quarter 2024 recorded net loss of $ -51.77 millions.

According to the results reported in the first quarter 2024, X4 Pharmaceuticals Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While X4 Pharmaceuticals Inc' s Net Income no change of % ranks overall at the positon no. in the first quarter 2024.




XFOR Net Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
X4 Pharmaceuticals Inc's first quarter 2024 Net Income $ -51.77 millions XFOR's Income Statement
X4 Pharmaceuticals Inc's first quarter 2023 Net Income $ -29.10 millions Quarterly XFOR's Income Statement
New: More XFOR's historic Net Income Growth >>


XFOR Net Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

X4 Pharmaceuticals Inc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Net Income Comment
Recent accomplishment of -51.77 millions by X4 Pharmaceuticals Inc come out even worse considering the -2.31 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Net Income growth. While X4 Pharmaceuticals Inc's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Net Income Comment
Recent results of -51.77 millions by X4 Pharmaceuticals Inc appear even less good compare to the -2.31 millions net loss in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Net Income growth. While X4 Pharmaceuticals Inc's Net Income growth quarter on quarter, overall rank is .


X4 Pharmaceuticals Inc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ -133.80 $ -111.14 $ -130.71 $ -96.21 $ -96.41
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
X4 Pharmaceuticals Inc' has realized cumulative trailing twelve months net loss of $ -134 millions in the Mar 31 2024 period.
The situation is worsening as the cumulative net loss is getting bigger from $ -111.14 millions in the twelve months ending a quarter before and $ -103.22 millions for the twelve months ending in the quarter Dec 31 2022.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
X4 Pharmaceuticals Inc' has realized cumulative trailing twelve months net loss of $ -134 millions in the Mar 31 2024 period.
The results are worsening as the cumulative net loss is becoming larger from $ -111.14 millions in the twelve months ending a quarter before and $ -103.22 millions for the twelve months ending in the quarter a year ago Joshua O. Anderson wrote.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
XFOR's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for XFOR's Competitors
Net Income Growth for X4 Pharmaceuticals Inc's Suppliers
Net Income Growth for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Dividend Payout Ratio
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2024
National Healthcare Corp132.62%$ 132.619 millions
Glucotrack Inc 127.60%$ 127.605 millions
Sotera Health Company122.48%$ 122.484 millions
Insulet Corporation116.39%$ 116.387 millions
Embecta Corp 106.43%$ 106.429 millions
Ligand Pharmaceuticals Incorporated105.34%$ 105.342 millions
Nature s Sunshine Products inc 98.72%$ 98.723 millions
Halozyme Therapeutics Inc 93.92%$ 93.924 millions
Carlisle Companies Incorporated89.09%$ 89.086 millions
Davita Inc 79.28%$ 79.284 millions
Biomarin Pharmaceutical Inc74.35%$ 74.353 millions
Corcept Therapeutics Inc74.06%$ 74.062 millions
Merck and Co Inc 68.74%$ 68.743 millions
Eli Lilly And Company66.77%$ 66.771 millions
Amphastar Pharmaceuticals Inc 65.86%$ 65.861 millions
Lemaitre Vascular Inc 63.69%$ 63.692 millions
Enzon Pharmaceuticals inc 62.44%$ 62.437 millions
Lifevantage Corp62.33%$ 62.329 millions
Vertex Pharmaceuticals Inc57.13%$ 57.131 millions
Boston Scientific Corporation57.01%$ 57.006 millions
Integer Holdings Corporation56.97%$ 56.969 millions
Intuitive Surgical Inc 51.72%$ 51.718 millions
Shockwave Medical Inc 41.46%$ 41.459 millions
Medpace Holdings Inc 40.74%$ 40.740 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com